Breast Cancer, Drugmaker | featured news

If you want the FDA to approve more innovative, new drugs based on promising but early clinical results, you have to give the FDA a way to revoke those approvals later on, should larger trials prove that those drugs aren't as safe or effective as they first seemed. This is why the FDA should be congratulated for the way it has handled the Avastin breast cancer saga, and why I hope we will see the FDA handle more cases like this one, not less.

The best-selling cancer drug in the world comes under federal scrutiny as drugmaker Roche makes a last-ditch effort to keep Avastin approved ...